RVMD Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
505.1M
+13.5%
445.2M
+23.1%
361.6M
+14.7%
315.3M
+19.1%
264.7M
R&D
394.9M
+14.8%
344.0M
+16.6%
294.9M
+12.4%
262.5M
+17.1%
224.1M
SG&A
110.2M
+8.9%
101.3M
+51.8%
66.7M
+26.4%
52.8M
+30.0%
40.6M
Operating Income
-505132000
-13.5%
-445222000
-23.1%
-361626000
-14.7%
-315269000
-19.1%
-264714000
EBITDA
-502683000
-13.5%
-442876000
-23.3%
-359290000
-14.8%
-312939000
-19.1%
-262689000
Net Income
-644371000
-42.0%
-453816000
-24.4%
-364892000
-19.6%
-305206000
-23.2%
-247787000
EPS (Basic)
$-3.06
-33.6%
$-2.29
-21.8%
$-1.88
-16.8%
$-1.61
-22.9%
$-1.31
EPS (Diluted)
$-3.06
-33.6%
$-2.29
-21.8%
$-1.88
-16.8%
$-1.61
-22.9%
$-1.31
Shares (Diluted)
210.9M
+6.5%
198.1M
+1.8%
194.6M
+2.8%
189.2M
+0.3%
188.6M
Revolution Medicines (RVMD) โ€” Financials